Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mycoses | 8 | 2018 | 389 | 2.370 |
Why?
|
Antifungal Agents | 10 | 2022 | 731 | 1.850 |
Why?
|
Aspergillosis | 7 | 2019 | 236 | 1.750 |
Why?
|
Mannans | 4 | 2018 | 62 | 1.620 |
Why?
|
beta-Glucans | 7 | 2020 | 124 | 1.430 |
Why?
|
Volatile Organic Compounds | 2 | 2021 | 81 | 0.860 |
Why?
|
Communicable Diseases | 3 | 2021 | 892 | 0.790 |
Why?
|
Breath Tests | 2 | 2021 | 291 | 0.750 |
Why?
|
Ascomycota | 2 | 2012 | 85 | 0.740 |
Why?
|
Pulmonary Aspergillosis | 1 | 2018 | 47 | 0.630 |
Why?
|
False Positive Reactions | 2 | 2018 | 965 | 0.610 |
Why?
|
Immunocompromised Host | 5 | 2015 | 847 | 0.580 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2022 | 1389 | 0.560 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2018 | 773 | 0.560 |
Why?
|
Disk Diffusion Antimicrobial Tests | 1 | 2015 | 9 | 0.550 |
Why?
|
Candidemia | 1 | 2015 | 29 | 0.540 |
Why?
|
Lung Transplantation | 3 | 2017 | 1139 | 0.530 |
Why?
|
Fluconazole | 1 | 2015 | 146 | 0.520 |
Why?
|
Cephalosporins | 1 | 2016 | 202 | 0.500 |
Why?
|
Neuralgia, Postherpetic | 1 | 2013 | 39 | 0.460 |
Why?
|
Antigens, Fungal | 2 | 2012 | 70 | 0.460 |
Why?
|
Aspergillus fumigatus | 1 | 2014 | 151 | 0.450 |
Why?
|
Clinical Laboratory Techniques | 1 | 2018 | 740 | 0.440 |
Why?
|
Pneumonia, Pneumocystis | 2 | 2012 | 246 | 0.430 |
Why?
|
Opportunistic Infections | 1 | 2015 | 384 | 0.430 |
Why?
|
Heart Transplantation | 3 | 2017 | 3123 | 0.430 |
Why?
|
Parainfluenza Virus 3, Human | 1 | 2012 | 24 | 0.420 |
Why?
|
Candidiasis, Invasive | 1 | 2012 | 22 | 0.420 |
Why?
|
Paramyxoviridae Infections | 1 | 2012 | 59 | 0.410 |
Why?
|
Mycophenolic Acid | 1 | 2013 | 335 | 0.400 |
Why?
|
Anti-Infective Agents, Local | 1 | 2014 | 250 | 0.390 |
Why?
|
Herpes Zoster | 1 | 2013 | 264 | 0.380 |
Why?
|
Neutropenia | 1 | 2016 | 893 | 0.380 |
Why?
|
Central Nervous System Fungal Infections | 1 | 2010 | 25 | 0.370 |
Why?
|
Galactose | 4 | 2018 | 303 | 0.370 |
Why?
|
Cytomegalovirus Infections | 5 | 2020 | 817 | 0.360 |
Why?
|
Hematologic Neoplasms | 4 | 2020 | 1856 | 0.360 |
Why?
|
Cellulitis | 1 | 2012 | 210 | 0.360 |
Why?
|
Catheterization, Central Venous | 1 | 2014 | 516 | 0.330 |
Why?
|
Myositis | 1 | 2012 | 247 | 0.330 |
Why?
|
Triazoles | 4 | 2019 | 909 | 0.320 |
Why?
|
Cord Blood Stem Cell Transplantation | 3 | 2018 | 312 | 0.310 |
Why?
|
Hematopoietic Stem Cell Transplantation | 6 | 2022 | 5469 | 0.300 |
Why?
|
Transplantation, Homologous | 6 | 2018 | 4794 | 0.300 |
Why?
|
Ethanol | 1 | 2014 | 1346 | 0.300 |
Why?
|
Cytomegalovirus | 4 | 2020 | 734 | 0.290 |
Why?
|
Immunosuppressive Agents | 4 | 2013 | 4121 | 0.270 |
Why?
|
Recombinant Fusion Proteins | 2 | 2012 | 3761 | 0.260 |
Why?
|
Proteoglycans | 5 | 2012 | 834 | 0.250 |
Why?
|
Candidiasis | 2 | 2021 | 370 | 0.240 |
Why?
|
Extracorporeal Membrane Oxygenation | 3 | 2020 | 1379 | 0.240 |
Why?
|
Frontal Lobe | 1 | 2010 | 1398 | 0.230 |
Why?
|
Graft Rejection | 2 | 2013 | 4370 | 0.230 |
Why?
|
Physicians | 1 | 2021 | 4625 | 0.220 |
Why?
|
Aged | 32 | 2020 | 165629 | 0.210 |
Why?
|
Immunologic Factors | 2 | 2018 | 1572 | 0.210 |
Why?
|
Organ Transplantation | 3 | 2022 | 1127 | 0.200 |
Why?
|
Immunoassay | 2 | 2020 | 749 | 0.200 |
Why?
|
Antibodies, Monoclonal | 2 | 2010 | 9300 | 0.200 |
Why?
|
Middle Aged | 35 | 2020 | 216054 | 0.200 |
Why?
|
Histoplasma | 2 | 2011 | 41 | 0.200 |
Why?
|
Cardiomyopathies | 1 | 2013 | 1895 | 0.200 |
Why?
|
Histoplasmosis | 2 | 2011 | 66 | 0.200 |
Why?
|
Anti-Bacterial Agents | 2 | 2017 | 7269 | 0.190 |
Why?
|
Young Adult | 13 | 2020 | 57267 | 0.190 |
Why?
|
Glucans | 1 | 2020 | 72 | 0.180 |
Why?
|
Respiratory Insufficiency | 2 | 2019 | 1211 | 0.180 |
Why?
|
Transplants | 1 | 2022 | 209 | 0.180 |
Why?
|
Adult | 29 | 2022 | 216658 | 0.180 |
Why?
|
Sepsis | 1 | 2014 | 2604 | 0.170 |
Why?
|
Male | 38 | 2021 | 354311 | 0.170 |
Why?
|
Humans | 56 | 2022 | 752741 | 0.170 |
Why?
|
Leukemia | 1 | 2008 | 1520 | 0.170 |
Why?
|
Pneumocystis carinii | 2 | 2012 | 73 | 0.170 |
Why?
|
Aged, 80 and over | 12 | 2020 | 58361 | 0.170 |
Why?
|
Polydeoxyribonucleotides | 1 | 2020 | 127 | 0.170 |
Why?
|
Fever | 3 | 2018 | 1627 | 0.160 |
Why?
|
Adrenal Glands | 2 | 2011 | 557 | 0.160 |
Why?
|
Lymphoma | 1 | 2008 | 1892 | 0.160 |
Why?
|
Orchitis | 1 | 2018 | 35 | 0.160 |
Why?
|
Encephalitis, Tick-Borne | 1 | 2018 | 34 | 0.160 |
Why?
|
Respiratory Tract Infections | 2 | 2020 | 980 | 0.150 |
Why?
|
Encephalitis Viruses, Tick-Borne | 1 | 2018 | 40 | 0.150 |
Why?
|
Uveitis | 2 | 2011 | 381 | 0.150 |
Why?
|
Female | 33 | 2020 | 385090 | 0.150 |
Why?
|
Molecular Diagnostic Techniques | 3 | 2020 | 609 | 0.150 |
Why?
|
Encephalitozoon cuniculi | 1 | 2017 | 5 | 0.150 |
Why?
|
Photopheresis | 1 | 2017 | 24 | 0.150 |
Why?
|
Microsporidiosis | 1 | 2017 | 23 | 0.150 |
Why?
|
Cohort Studies | 11 | 2019 | 40939 | 0.150 |
Why?
|
Anticoagulants | 4 | 2005 | 4738 | 0.140 |
Why?
|
Viruses | 1 | 2020 | 377 | 0.140 |
Why?
|
Heart Defects, Congenital | 1 | 2013 | 4638 | 0.140 |
Why?
|
Primary Graft Dysfunction | 1 | 2017 | 95 | 0.140 |
Why?
|
Incidence | 6 | 2022 | 21146 | 0.130 |
Why?
|
Hemorrhage | 2 | 2004 | 3530 | 0.130 |
Why?
|
Cyclohexenes | 1 | 2014 | 15 | 0.130 |
Why?
|
Retrospective Studies | 13 | 2022 | 78758 | 0.130 |
Why?
|
Monoterpenes | 1 | 2014 | 21 | 0.130 |
Why?
|
Lung Diseases, Fungal | 1 | 2015 | 125 | 0.130 |
Why?
|
Risk Factors | 10 | 2022 | 73094 | 0.130 |
Why?
|
Treatment Outcome | 12 | 2019 | 64017 | 0.120 |
Why?
|
Antineoplastic Agents | 3 | 2019 | 13678 | 0.120 |
Why?
|
Terpenes | 1 | 2014 | 100 | 0.120 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2014 | 362 | 0.120 |
Why?
|
Decision Trees | 1 | 2015 | 506 | 0.120 |
Why?
|
Sesquiterpenes | 1 | 2014 | 176 | 0.110 |
Why?
|
Herpes Zoster Ophthalmicus | 1 | 2013 | 37 | 0.110 |
Why?
|
Species Specificity | 1 | 2018 | 2483 | 0.110 |
Why?
|
Leukemia, Prolymphocytic, T-Cell | 1 | 2013 | 21 | 0.110 |
Why?
|
Encephalomyelitis | 1 | 2013 | 35 | 0.110 |
Why?
|
Encephalitis | 1 | 2017 | 429 | 0.110 |
Why?
|
Ganciclovir | 1 | 2013 | 257 | 0.110 |
Why?
|
Immunomodulation | 1 | 2017 | 545 | 0.110 |
Why?
|
Echinocandins | 1 | 2012 | 44 | 0.110 |
Why?
|
Adenoviridae Infections | 1 | 2013 | 97 | 0.110 |
Why?
|
DNA, Ribosomal Spacer | 1 | 2012 | 25 | 0.110 |
Why?
|
Reagent Strips | 1 | 2012 | 39 | 0.110 |
Why?
|
Lipopeptides | 1 | 2012 | 74 | 0.100 |
Why?
|
Limbic Encephalitis | 1 | 2012 | 34 | 0.100 |
Why?
|
Amphotericin B | 1 | 2012 | 141 | 0.100 |
Why?
|
Tissue Transplantation | 1 | 2012 | 130 | 0.100 |
Why?
|
Serum | 2 | 2011 | 213 | 0.100 |
Why?
|
Immunotherapy | 1 | 2008 | 4526 | 0.100 |
Why?
|
Aspergillus | 1 | 2012 | 86 | 0.100 |
Why?
|
Epidemiologic Studies | 1 | 2015 | 679 | 0.100 |
Why?
|
Roseolovirus Infections | 1 | 2012 | 46 | 0.100 |
Why?
|
Cytosine | 1 | 2013 | 216 | 0.100 |
Why?
|
Marital Status | 1 | 2013 | 440 | 0.100 |
Why?
|
Herpesvirus 6, Human | 1 | 2012 | 95 | 0.100 |
Why?
|
Antibiotic Prophylaxis | 1 | 2017 | 647 | 0.100 |
Why?
|
Cystectomy | 1 | 2017 | 693 | 0.100 |
Why?
|
Drug Administration Schedule | 3 | 2015 | 4943 | 0.100 |
Why?
|
Candida | 1 | 2012 | 171 | 0.100 |
Why?
|
Equipment Contamination | 1 | 2012 | 184 | 0.090 |
Why?
|
DNA, Ribosomal | 1 | 2012 | 291 | 0.090 |
Why?
|
DNA, Fungal | 1 | 2012 | 280 | 0.090 |
Why?
|
Early Diagnosis | 1 | 2015 | 1181 | 0.090 |
Why?
|
Time Factors | 7 | 2019 | 40195 | 0.090 |
Why?
|
Costs and Cost Analysis | 1 | 2015 | 1687 | 0.090 |
Why?
|
Diagnostic Tests, Routine | 1 | 2015 | 784 | 0.090 |
Why?
|
Graft vs Host Disease | 3 | 2012 | 2957 | 0.090 |
Why?
|
Anti-Infective Agents | 2 | 2014 | 980 | 0.080 |
Why?
|
Histocytochemistry | 1 | 2010 | 719 | 0.080 |
Why?
|
Kidney Transplantation | 2 | 2017 | 4185 | 0.080 |
Why?
|
Dacarbazine | 1 | 2012 | 567 | 0.080 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2010 | 697 | 0.080 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2012 | 621 | 0.080 |
Why?
|
Seminal Vesicles | 2 | 2005 | 103 | 0.080 |
Why?
|
Drug Costs | 1 | 2015 | 1117 | 0.080 |
Why?
|
Respiration, Artificial | 1 | 2019 | 2611 | 0.080 |
Why?
|
Tissue Donors | 1 | 2017 | 2234 | 0.070 |
Why?
|
Aminoglycosides | 1 | 2008 | 162 | 0.070 |
Why?
|
Fatal Outcome | 3 | 2018 | 1859 | 0.070 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2020 | 4403 | 0.070 |
Why?
|
Republic of Korea | 2 | 2019 | 557 | 0.070 |
Why?
|
Lung Diseases | 1 | 2017 | 1890 | 0.070 |
Why?
|
Leg | 1 | 2012 | 1123 | 0.070 |
Why?
|
Face | 1 | 2012 | 1008 | 0.070 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2010 | 457 | 0.070 |
Why?
|
Antibodies, Neoplasm | 1 | 2008 | 286 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2017 | 2295 | 0.070 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12250 | 0.070 |
Why?
|
Immunity, Humoral | 1 | 2010 | 596 | 0.070 |
Why?
|
Proportional Hazards Models | 3 | 2020 | 12423 | 0.070 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4549 | 0.070 |
Why?
|
Treatment Failure | 1 | 2012 | 2642 | 0.070 |
Why?
|
Liver Transplantation | 1 | 2017 | 2137 | 0.070 |
Why?
|
Warfarin | 2 | 2004 | 1515 | 0.070 |
Why?
|
Survival Rate | 3 | 2019 | 12802 | 0.070 |
Why?
|
Combined Modality Therapy | 2 | 2017 | 8660 | 0.070 |
Why?
|
Academic Medical Centers | 1 | 2016 | 2761 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2015 | 10057 | 0.060 |
Why?
|
Feasibility Studies | 1 | 2015 | 5144 | 0.060 |
Why?
|
Microscopy | 1 | 2010 | 903 | 0.060 |
Why?
|
Prognosis | 4 | 2020 | 29264 | 0.060 |
Why?
|
Cluster Analysis | 1 | 2012 | 2719 | 0.060 |
Why?
|
Radiotherapy, Conformal | 2 | 2005 | 552 | 0.060 |
Why?
|
Sirolimus | 1 | 2012 | 1568 | 0.060 |
Why?
|
Prostate-Specific Antigen | 2 | 2005 | 2517 | 0.060 |
Why?
|
Boston | 2 | 2016 | 9348 | 0.060 |
Why?
|
Adolescent | 7 | 2020 | 86713 | 0.060 |
Why?
|
Phylogeny | 1 | 2012 | 2820 | 0.060 |
Why?
|
Diagnostic Errors | 1 | 2011 | 1270 | 0.060 |
Why?
|
Antiviral Agents | 2 | 2013 | 3012 | 0.060 |
Why?
|
Kinetics | 1 | 2012 | 6482 | 0.060 |
Why?
|
Thromboembolism | 3 | 2005 | 996 | 0.060 |
Why?
|
Medication Systems, Hospital | 1 | 2004 | 157 | 0.060 |
Why?
|
Sensitivity and Specificity | 2 | 2009 | 14761 | 0.060 |
Why?
|
Recurrence | 1 | 2015 | 8422 | 0.060 |
Why?
|
Bandages | 1 | 2005 | 267 | 0.060 |
Why?
|
Surgical Wound Infection | 1 | 2012 | 1552 | 0.060 |
Why?
|
Influenza Vaccines | 1 | 2010 | 762 | 0.050 |
Why?
|
Drug Therapy, Computer-Assisted | 1 | 2004 | 204 | 0.050 |
Why?
|
Adrenal Cortex Hormones | 1 | 2012 | 1867 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 5410 | 0.050 |
Why?
|
Postoperative Complications | 2 | 2017 | 15459 | 0.050 |
Why?
|
Predictive Value of Tests | 1 | 2018 | 15164 | 0.050 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2004 | 346 | 0.050 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2011 | 1060 | 0.050 |
Why?
|
Health Care Costs | 1 | 2015 | 3217 | 0.050 |
Why?
|
Anti-Inflammatory Agents | 1 | 2012 | 1812 | 0.050 |
Why?
|
Reminder Systems | 1 | 2005 | 377 | 0.050 |
Why?
|
Massachusetts | 1 | 2014 | 8721 | 0.050 |
Why?
|
Cause of Death | 1 | 2012 | 3628 | 0.050 |
Why?
|
Sequence Analysis, DNA | 1 | 2012 | 4806 | 0.050 |
Why?
|
GATA2 Transcription Factor | 1 | 2021 | 160 | 0.050 |
Why?
|
Heparin | 2 | 2004 | 1653 | 0.050 |
Why?
|
Risk | 1 | 2012 | 9683 | 0.040 |
Why?
|
Antigens, CD19 | 1 | 2022 | 400 | 0.040 |
Why?
|
Sex Factors | 1 | 2013 | 10469 | 0.040 |
Why?
|
Antibodies, Viral | 1 | 2010 | 3194 | 0.040 |
Why?
|
Radiography | 1 | 2010 | 7047 | 0.040 |
Why?
|
Influenza, Human | 1 | 2010 | 1515 | 0.040 |
Why?
|
Myasthenia Gravis | 2 | 2011 | 205 | 0.040 |
Why?
|
Stem Cell Transplantation | 1 | 2008 | 1626 | 0.040 |
Why?
|
Molecular Sequence Data | 1 | 2012 | 18050 | 0.040 |
Why?
|
North America | 1 | 2022 | 1255 | 0.040 |
Why?
|
Neoplasms | 2 | 2021 | 21976 | 0.040 |
Why?
|
APACHE | 1 | 2019 | 277 | 0.040 |
Why?
|
Cell Count | 1 | 2022 | 1856 | 0.040 |
Why?
|
Follow-Up Studies | 4 | 2014 | 39223 | 0.040 |
Why?
|
Pyrimidines | 1 | 2010 | 2987 | 0.040 |
Why?
|
Medication Errors | 1 | 2004 | 799 | 0.040 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2020 | 217 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11626 | 0.040 |
Why?
|
Blood Glucose | 1 | 2012 | 6318 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2019 | 2888 | 0.040 |
Why?
|
Adenocarcinoma | 2 | 2005 | 6387 | 0.040 |
Why?
|
Glioblastoma | 1 | 2012 | 3494 | 0.040 |
Why?
|
Age Factors | 1 | 2013 | 18460 | 0.030 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 1622 | 0.030 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2008 | 4420 | 0.030 |
Why?
|
Risk Assessment | 3 | 2014 | 23554 | 0.030 |
Why?
|
Prospective Studies | 2 | 2014 | 53863 | 0.030 |
Why?
|
Hospital Mortality | 2 | 2020 | 5367 | 0.030 |
Why?
|
Area Under Curve | 1 | 2020 | 1654 | 0.030 |
Why?
|
Decision Support Systems, Clinical | 1 | 2005 | 1185 | 0.030 |
Why?
|
Venous Thrombosis | 1 | 2005 | 1295 | 0.030 |
Why?
|
Acute Disease | 2 | 2019 | 7221 | 0.030 |
Why?
|
Nitriles | 1 | 2019 | 960 | 0.030 |
Why?
|
Fatigue | 2 | 2011 | 1536 | 0.030 |
Why?
|
Multiple Myeloma | 1 | 2011 | 5076 | 0.030 |
Why?
|
Software | 2 | 2005 | 4460 | 0.030 |
Why?
|
Immunotherapy, Adoptive | 1 | 2022 | 1355 | 0.030 |
Why?
|
Consensus | 1 | 2022 | 3023 | 0.030 |
Why?
|
Bacteria, Aerobic | 1 | 2012 | 25 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 1998 | 1054 | 0.030 |
Why?
|
Bacteria, Anaerobic | 1 | 2012 | 68 | 0.030 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 685 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2019 | 3500 | 0.030 |
Why?
|
ROC Curve | 1 | 2020 | 3558 | 0.030 |
Why?
|
Drug Dosage Calculations | 1 | 2012 | 114 | 0.030 |
Why?
|
Pulmonary Embolism | 1 | 2005 | 2481 | 0.020 |
Why?
|
Fetal Blood | 1 | 2018 | 1332 | 0.020 |
Why?
|
Prostatic Neoplasms | 2 | 2005 | 11211 | 0.020 |
Why?
|
Phlebotomy | 1 | 2012 | 141 | 0.020 |
Why?
|
Severity of Illness Index | 3 | 2019 | 15657 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 2 | 2010 | 35798 | 0.020 |
Why?
|
Virus Activation | 1 | 2012 | 319 | 0.020 |
Why?
|
Hodgkin Disease | 1 | 1998 | 1417 | 0.020 |
Why?
|
Weight Loss | 2 | 2011 | 2679 | 0.020 |
Why?
|
United States | 3 | 2017 | 70772 | 0.020 |
Why?
|
Catheter-Related Infections | 1 | 2012 | 254 | 0.020 |
Why?
|
Linear Models | 1 | 2020 | 5965 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2020 | 5974 | 0.020 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 1517 | 0.020 |
Why?
|
SEER Program | 1 | 2013 | 1510 | 0.020 |
Why?
|
Radiotherapy Dosage | 2 | 2005 | 2893 | 0.020 |
Why?
|
Drug Synergism | 1 | 2012 | 1768 | 0.020 |
Why?
|
Pyridines | 1 | 2019 | 2841 | 0.020 |
Why?
|
Cytokines | 1 | 2020 | 7400 | 0.020 |
Why?
|
Disease-Free Survival | 2 | 2005 | 6920 | 0.020 |
Why?
|
Social Support | 1 | 2013 | 2145 | 0.010 |
Why?
|
Length of Stay | 1 | 2017 | 6355 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2012 | 6352 | 0.010 |
Why?
|
Hospital Information Systems | 1 | 2005 | 396 | 0.010 |
Why?
|
Graft Survival | 1 | 2012 | 3731 | 0.010 |
Why?
|
Chronic Disease | 1 | 2017 | 9223 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2012 | 6493 | 0.010 |
Why?
|
Radionuclide Imaging | 1 | 2005 | 2030 | 0.010 |
Why?
|
Odds Ratio | 1 | 2013 | 9863 | 0.010 |
Why?
|
Pneumonia | 1 | 2012 | 2154 | 0.010 |
Why?
|
Risk Management | 1 | 2004 | 563 | 0.010 |
Why?
|
Survival Analysis | 1 | 2012 | 10252 | 0.010 |
Why?
|
Sex Distribution | 1 | 2004 | 2304 | 0.010 |
Why?
|
Probability | 1 | 2004 | 2514 | 0.010 |
Why?
|
Medical Records Systems, Computerized | 1 | 2005 | 1203 | 0.010 |
Why?
|
Intracranial Hemorrhages | 1 | 2004 | 863 | 0.010 |
Why?
|
Age Distribution | 1 | 2004 | 2905 | 0.010 |
Why?
|
Costa Rica | 1 | 1998 | 177 | 0.010 |
Why?
|
Reed-Sternberg Cells | 1 | 1998 | 73 | 0.010 |
Why?
|
Viral Matrix Proteins | 1 | 1998 | 188 | 0.010 |
Why?
|
Prostate | 1 | 2005 | 1794 | 0.010 |
Why?
|
Mutation | 1 | 2021 | 29981 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2004 | 3627 | 0.010 |
Why?
|
Forecasting | 1 | 2005 | 2956 | 0.010 |
Why?
|
Quality Assurance, Health Care | 1 | 2005 | 2215 | 0.010 |
Why?
|
Immunophenotyping | 1 | 1998 | 1875 | 0.010 |
Why?
|
Biopsy | 1 | 2005 | 6771 | 0.010 |
Why?
|
Patient Care Team | 1 | 2004 | 2555 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2004 | 10914 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 1998 | 6169 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2011 | 20346 | 0.000 |
Why?
|
Research Design | 1 | 2004 | 6118 | 0.000 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2005 | 9305 | 0.000 |
Why?
|
Animals | 1 | 2018 | 169600 | 0.000 |
Why?
|
Hospitalization | 1 | 2004 | 10422 | 0.000 |
Why?
|
Immunohistochemistry | 1 | 1998 | 11395 | 0.000 |
Why?
|
Socioeconomic Factors | 1 | 1998 | 7852 | 0.000 |
Why?
|
Cross-Sectional Studies | 1 | 2004 | 25454 | 0.000 |
Why?
|